 Jounce Therapeutics, Inc. JNCE, a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the presentation of new preclinical data from its JTX-1811 program and translational data from its ongoing vopratelimab program at the American Association for Cancer Research AACR Virtual Annual Meeting. Tumor-infiltrating T-regulatory TITR cells suppress anti-tumor immunity in the tumor microenvironment. 